Since 1996 Erchonia, the manufacturer of ZERONA®, has been committed to fully bringing to light the medical utility of low-level laser therapy (3LT®) through rigorous clinical studies.
ZERONA® has been examined extensively from in-vitro and ex-vivo analyses to in-vivo clinical investigations.
Presently, Erchonia remains steadfast in unlocking the potential benefits of ZERONA® by exploring subtle changes within adipocyte function that could modulate DNA expression, protein and hormone synthesis, ultimately affecting the endocrine and immune systems.
The ZERONA® procedure has been proven through a double-blind, randomized, multi-site and placebo-controlled clinical study in which clients, on average, lost 3.72 inches from their waist, hips and thighs. These results were dramatic compared to the placebo group, which only lost an average of half an inch over the same time period.
As you will quickly learn, ZERONA® was built on a solid foundation of histological and clinical evidence and should reassure you and your clinic that ZERONA® will provide clients with a reliable, safe and effective non-invasive contouring of the waist, hips, thighs and arms.
Erchonia has developed other products that are designed and FDA market cleared for use during liposuction and breast augmentation. This led to the non-invasive ZERONA® laser, which emulsifies the adipose tissue and releases excess fat into the interstitial space. From there, fat is passed through the body during its normal course of detoxification.
CALL TODAY 520-390-2966
